Status:
WITHDRAWN
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors
Lead Sponsor:
Genmab
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A Single-arm Phase II Trial Investigating the Efficacy and Safety of Zalutumumab in Patients with Non-Small Cell Lung Cancer who have Progressive Disease after Treatment with Tyrosine Kinase Inhibitor...
Eligibility Criteria
Inclusion
- Patients must have documented disease progression after TKI treatment (verified by CT scan and/or MRI according to RECIST).
Exclusion
- Estimated life expectancy of less than 3 months.
- Received the following treatments within 2 weeks prior to Visit 2:
- Cytotoxic or cytostatic anti-cancer chemotherapy
- Total resection or irradiation of the target lesion
- Any investigational agent
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01449357
Last Update
October 10 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.